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Techniques of assessing small airways dysfunction
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The small airways are defined as those less than 2 mm in diameter. They are a major site of pathology in many
lung diseases, not least chronic obstructive pulmonary disease (COPD) and asthma. The small airways are
frequently involved early in the course of these diseases, with significant pathology demonstrable often before
the onset of symptoms or changes in spirometry and imaging. Despite their importance, they have proven
relatively difficult to study. This is in part due to their relative inaccessibility to biopsy and their small size
which makes their imaging difficult. Traditional lung function tests may only become abnormal once there is
a significant burden of disease within them. This has led to the term ‘the quiet zone’ of the lung. In recent
years, more specialised tests have been developed which may detect these changes earlier, perhaps offering the
possibility of earlier diagnosis and intervention. These tests are now moving from the realms of clinical
research laboratories into routine clinical practice and are increasingly useful in the diagnosis and monitoring
of respiratory diseases. This article gives an overview of small airways physiology and some of the routine and
more advanced tests of airway function.
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T
he airways consist of approximately 23 genera-
tions of dichotomously branching tubes from the
trachea to the alveoli (1) (Fig. 1). The main func-
tion of the airways is to ventilate the gas exchanging units
of the lung. They also play a role in the conditioning of
inhaled air, removal of particulate matter, and immune
defence within the lung.
The first 15 generations of airways are called the
conducting airways and take no part in gas exchange.
They constitute the anatomical dead space, which is
approximately 100150 ml in a human adult (2). Beyond
this region lie the respiratory bronchioles which have
occasional alveoli budding from them. These continue to
divide until they reach the alveolar sacs with a total
surface area of 7080 m2 (3). These airways take part in
gas exchange and comprise the acinar airways.
The small airways refer to those airways less than 2 mm
in diameter (4). These occur from approximately genera-
tion 8 and include a portion of the conducting airways as
well as all the acinar airways. They have important struc-
tural and physiological differences from large airways.
First, they lack the cartilaginous support seen in large air-
ways and lack mucous glands. They are lined by surfactant
which reduces surface tension and helps prevent them
from closing on expiration and at low lung volumes (5).
Throughout successive airway generations, there is a
reduction in the length and diameter of the airway.
Because of the exponential increase in airway numbers,
there is a rapid increase in cross-sectional area with each
subsequent generation. This has two major effects on
airway physiology. First, for any given flow, the velocity
of gas transit within the lung decreases with increasing
airway generation. The result of this is high velocity flow
in the proximal airways which is turbulent and hence
density dependent. In the small airways of the lung,
flow is laminar and therefore independent of gas density
(6). At the interface of the conducting and acinar airways,
there is a change from bulk convective flow to diffusion
down a concentration gradient. However the distance
for diffusion is small, approximately 0.2 mm (7). Second,
the resistance to airflow in the small airways is low in
health, comprising between 10 and 25% of total airways
resistance (8, 9). However, small airways resistance is sig-
nificantly increased in disease (10). Small airways resis-
tance is largely independent of lung volume whilst large
airways resistance is altered significantly with change in
lung volumes (8). These arrangements in the human lung
help to achieve as equitable ventilation to lung units as
possible, whilst maintaining low airflow resistance and
minimal work of breathing.
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The small airways in disease
Both in chronic obstructive pulmonary disease (COPD)
and asthma, the small airways have been shown to be the
major site of airflow obstruction (9, 11, 12). The small
airways may be more prone to pathology because of their
size. Small inhaled particles and pathogens may be
deposited here and pathological changes in airways disease
make the small airways susceptible to occlusion. There-
fore, small airways may require inhaled therapeutic aero-
sols of smaller size to be able to penetrate the airways tree
and reach the distal lung region (13). Pouseille’s law states
that the resistance to flow is inversely proportional to the
fourth power of the radius. Hence, airway obstruction can
have profound effects on lung physiology. The obstruction
of small airways can occur through a number of mechan-
isms, including luminal occlusion by mucus, reduction in
luminal diameter from inflammatory infiltrates, smooth
muscle hypertrophy, or airway wall thickening. In addi-
tion, loss of structural airway supports may enhance
collapsibility of airways.
Asthma
In asthma, the small airways are thickened with a chronic
inflammatory infiltrate affecting all layers of the airway
(14). Inflammatory changes are present throughout the
airways, although differences in the extent and composi-
tion of the inflammatory infiltrate exist between large
and small airways. The small airways are the major
site of inflammation in asthma (15, 16) with a chro-
nic inflammatory infiltrate consisting of eosinophils, T-
lymphocytes, neutrophils, and macrophages. In addition,
there is smooth muscle thickening and luminal occlusion
by mucus (1719). In small airways, the density of the
lymphocytes and eosinophils is greater in the outer walls
compared to large airways where more central airway
wall inflammation predominates (15, 20). Mast cells are
found more commonly in the periphery of the lung (21)
than the central airways and more marked neutrophilic
inflammation may be seen in the peribronchiolar lung
parenchyma in fatal asthma (15). The severity of inflam-
matory changes correlates with lung function in nocturnal
asthma (22), severe asthma (21), and is more marked
in patients with fatal asthma compared to non-fatal
asthma (23).
Chronic obstructive pulmonary disease
COPD is characterised predominately by neutrophilic
and lymphocytic small airway infiltration along with the
presence of (2426). Lymphocytic infiltration and smooth
muscle hypertrophy are more prominent in COPD than in
Fig. 1. Airway generations (adapted from ref. 1).
William McNulty and Omar S. Usmani
2
(page number not for citation purpose)
Citation: European Clinical Respiratory Journal 2014, 1: 25898 - http://dx.doi.org/10.3402/ecrj.v1.25898
asymptomatic smokers (25). In addition, there is airway
remodelling with peribronchial fibrosis, smooth muscle
hypertrophy, and luminal occlusion from mucus (27, 28).
The extent of airway inflammation correlates with disease
severity in COPD (24, 29, 30). However, it is airway wall
thickness, rather than the severity of inflammatory
changes, that is more strongly associated with disease
progression in COPD (30). This suggests that regulation
of the remodelling pathways through tissue growth factors
may be altered in susceptible patients. Interestingly,
smoking has been shown to increase tissue levels of
growth factors that promote airway remodelling prior to
the onset of inflammatory changes (31). Emphysematous
destruction of lung tissue may also affect the small
airways by disruption of the elastic fibres supporting
airway walls. The extent of airway inflammation corre-
lates with the degree of disruption (32) suggesting that
peribronchiolar inflammation may drive the protease-
mediated disruption of airway attachments. Indeed, small
airways disease may precede emphysematous changes
identified by computed tomography (CT) (33).
Inflammatory small airways disease may exacerbate
small airways injury and dysfunction through mechanical
stresses of cyclic opening and closing of airways during
tidal breathing.
Physiological assessment of the small airways
Small airways obstruction may lead to a reduction in
airflow, increased airways resistance, gas trapping, and
inhomogeneity of ventilation. Consequently, physiological
tests measuring these variables can detect and quantify
small airways disease (34). Table 1 summarises the tech-
niques available for the assessment of small airways
disease.
Spirometry
Spirometry is the most widely used lung function test
both in the diagnosis and stratification of severity of lung
disease. A diagnosis of obstructive lung disease is made
when the ratio of the Forced Expiratory Volume in 1 sec
(FEV1) to Forced Vital Capacity (FVC) is less than 70%
(35). Whilst a reduction in FEV1 may reflect airflow
obstruction, it is also dependent on lung volumes, elastic
recoil, respiratory muscle strength, and patient effort
(36). In health, the main site of airways resistance occurs
in the 4th8th airway generations. Thus, FEV1 largely
reflects large airways obstruction, and a significant
amount of small airways disease must accumulate before
FEV1 becomes abnormal.
Examination of the mid-portion of expiratory flow
may offer more information on small airway pathology.
The Forced Expiratory Flow between 25 and 75% of the
FVC (FEF2575) is one of the most commonly cited
measures of small airways pathology. McFadden and
Linden postulated that the latter part of the vital capacity
was affected by increased resistance in small airways
as lung volume fell. Pathology in these airways causes
excessive airway narrowing and collapse at an earlier time
and closer to the alveolus during exhalation. This results
in a reduction in the maximum expiratory flow that can
be achieved (37). However, FEF2575 is dependent on the
FVC and therefore changes in FVC will affect the portion
of the flow-volume curve examined. If FEF2575 is not
adjusted for lung volume, there is poor reproducibility
(38). Another disadvantage is the sensitivity of the
FEF2575, as it is frequently normal if the FEV1/FVC
ratio is 75% (39). In addition, there is poor correlation
with other markers of small airways disease such as gas
trapping (40) and histological evidence of small airways
inflammation (41). The Forced Expiratory Volume in 3
sec (FEV3) to FVC ratio has been suggested as an
alternative measure of small airways disease. The fraction
of air not expired in the first 3 sec (1-FEV3/FVC) is also
calculated to estimate the growing proportion of long
time constant lung units. As FEV1/FVC falls, the FEV3/
FVC falls and the 1-FEV3/FVC rises. These measures
have a better accuracy than FEF2575, particularly in
advancing age (42).
Gibbons et al. (43) suggested that the change in FVC
following a histamine provocation is a better measure of
small airway dysfunction in asthmatic patients than the
fall in FEV1. A fall in FVC suggests small airway closure
and gas trapping. Other spirometric markers that have
been suggessted for assessment of small airways disease
have included the ratio of the FVC to slow vital capacity
(SVC) (44).
Plethysmography
Plethysmographic assessment of lung volumes provides a
sensitive measure of gas trapping and lung hyperinflation.
Hyperinflation may be defined as an abnormal elevation
of lung volumes at the end of expiration (45). It is a
function of airflow limitation, lung elastic recoil, and chest
wall compliance. Airway narrowing results in a prolonged
time constant for expiration, and airways may close
resulting in gas trapping. The residual volume (RV) is an
important measure of small airways dysfunction and may
be raised before the onset of abnormal spirometry in
asthma (46, 47). The RV correlates with the degree of
inflammatory changes in small airways in COPD (24) and
with peripheral airway resistance in asthma (48). Indeed,
improvement in asthma symptoms following treatment
with monteleukast correlated with the reduction in RV but
not spirometric parameters (49).
The residual volume/total lung capacity (RV/TLC) ratio
may be a more useful marker of gas trapping as the TLC
is frequently raised in obstructive lung disease. Sorkness
et al. demonstrated that the RV/TLC ratio is higher in
patients with severe asthma compared to non-severe
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asthma and correlates inversely with FVC (40). However,
the upper limit of normal value varies with age and sex and
therefore the predicted value may provide a better measure
of gas trapping than the absolute value.
Airways resistance (Raw) may also be measured by
assessing pressure and flow at the mouth during body
plethysmography. Airways resistance is increased in
obstructive lung diseases and is more sensitive to changes
than spirometry in detecting bronchodilation (50). How-
ever, it is not specific for the small airways which limits its
application in diagnosing and monitoring distal airways
disease (51).
Table 1. Summary of physiological and imaging techniques for assessing the small airways
Measures Pros Cons
Lung function
Spirometry FEV1, FEF2575, FEV1/FVC,
FEV3/FVC, FEV/SVC
Widely available
Reproducible
Standardised criteria
Relatively insensitive to early
disease and subtle changes
Effort dependent
Not specific to small airways
changes
Plethysmography RV, RV/TLC, airways
resistance
Widely available
Reproducible
Relatively easy to perform
Sensitive to early change
Not specific for small airways
disease
Effort dependent
Relatively time consuming
IOS Z, Rrs, Xrs Non-invasive and easy to perform
Effort independent
Reproducible
Intra-breath analysis
Equipment not widely available
Interference from swallowing and
upper airway artefact
Inert gas washout Closing capacity and closing
volume
Phase III slope: SIII, Sacin,
Scond
Sensitive to early change
Can distinguish between distal and
proximal airways disease
Difficult to perform, requiring
specialist equipment
Restricted to research settings
Exhaled nitric oxide FENO Easy and quick to perform
Hand-held analysers available
Sensitive to changes with treatment
in asthma
Unclear role in COPD
Affected by smoking status
Imaging
High resolution computed
tomography
Assessment of airway
changes
Assessment of gas trapping
(MLDE/I)
Widely available
Quick and easy to perform
Unable to visualise small airways
directly
Specialist software may be
required
No standardised measurements
Radiation dose
Hyperpolarised magnetic
resonance imaging
Apparent diffusion
co-efficient
Regional ventilation defects
Allows assessment of
heterogeneity in distribution of
disease
No radiation dose
Expensive Limited to research
applications
Nuclear medicine (scintigraphy,
SPECT, and PET)
Ventilation
Inhaled drug or receptor
distribution
Allows assessment of
heterogeneity in distribution of
disease
Can help target drugs to site of lung
Can be tailored to study individual
drugs or receptors
Radiation dose
Difficult to identify small airways
Some isotopes can be expensive
SPECT and PET not yet widely
available
FEV1forced expiratory volume in 1 sec; FEV3forced expiratory volume in 3 sec; FVCforced vital capacity; Rrsrespiratory system
resistance; Xrsrespiratory system reactance; Zimpedance; SVCslow vital capacity; RVresidual volume; TLCtotal lung
capacity; FEF2575forced expiratory flow at 2575% of vital capacity; FENOfractional expired nitric oxide; SacinDCDI contribution to
SnIII; ScondCDI contribution to SnIII; SIIIslope of phase III; MLDE/Iexpiratory to inspiration mean lung density; SPECTsingle photon
emission computed tomography; PETPositron emission tomography.
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Impulse oscillometry
Impulse oscillometry (IOS) applies oscillating pressure
variations in the form of random noise to the respiratory
system in order to determine the mechanical properties
of the lung. The multiple frequencies between 3 and 20 Hz
are applied over normal tidal breathing from a loudspeaker.
The resulting pressure and flow changes are measured
at the mouth and analysed in a Fourier transforma-
tion to determine the impedance (Z) of the respiratory
system. This is composed of the in-phase or ‘real’ part of
the impedance, known as resistance (Rrs), and the out of
phase or ‘imaginary’ part, called reactance (Xrs). In health,
Rrs is independent of oscillation frequency but becomes
frequency dependent in the presence of airways obstruc-
tion. Reactance is determined by the elastic and the
inertial properties of the lung and is frequency dependent.
At low frequencies, Xrs is negative and largely represents
the elastic forces within the lung. At high frequencies, Xrs
is positive and is determined by inertiance within the lung
resulting from acceleration of airflow. At a point where the
elastance and inertiance are equal and opposite, Xrs is 0.
This is known as the resonant frequency (Fres) and occurs
between 8 and 12 Hz in healthy patients (52).
Higher frequency signals (15 Hz) are absorbed by
the respiratory system before reaching the small airways
and hence reflect the contribution of large airways. Low
frequencies (5 Hz) penetrate deep into the lung and
therefore represent the whole lung. The contribution of
the distal airways may be determined by the difference
between R5 and R20, and therefore can give insight
into small airways pathology. However, the anatomical
location of the transition between the small and large
airways has not been determined (53). Despite this, there
is evidence that low frequency resistance and reactance
measurements correlate strongly with transpulmonary
resistance measured by oesophageal manometry (54) and
other traditional small airways measures (55).
When airway obstruction is present, Rrs becomes
frequency dependent with a predominant increase in low
frequency resistance. This has been shown to identify
patients with asthma (5659) and COPD (56, 60, 61).
Whilst Rrs does increase in early stage COPD (60),
reactance measures are better at identifying severity of
disease (62) and are more closely associated with other
parameters including FEV1 and measures of hyperinfla-
tion (61). Dyspnoea scores and health status correlate
significantly with R520 and X5 quality of life in stable
COPD and are sensitive to improvements following
exacerbations (63).
IOS also allows for the discrimination of inspiratory
and expiratory resistance and reactance. Inspiratory
minus expiratory reactance at 5 Hz (DX5) has been
shown to help discriminate between asthma and COPD
(64). In addition, it has also been shown to be a sensitive,
non-invasive method of detecting expiratory flow limita-
tion (EFL) in COPD. Expiratory reactance falls when
EFL is present as the pressure signals cannot pass the
choke point with in the airway (65, 66). This is likely to
be due to the enhanced collapsibility of airways in
expiration and is a major factor in the development of
dynamic hyperinflation. Indeed, recent studies using R520
as an index of distal airway abnormality have shown the
presence of small airways dysfunction even in patients
with mild-moderate asthma (67).
Studies examining the effect of inhaled therapies on
lung mechanics have demonstrated that IOS is sensitive
to bronchodilation in both COPD (50, 68) and asthma
(69, 70). It has also been used in the assessment of lung
transplant recipients for bronchiolitis obliterans (71) and
following environmental exposure to dusts (72, 73).
IOS has the advantage of being simple to use and is
effort independent. It provides continuous measurement
of pulmonary mechanics giving a high temporal resolution
allowing intra-breath analysis. As IOS does not rely on
forced manoeuvres, it may be more suitable for patients
who cannot perform these easily such as children or those
with severe lung diseases. This may also reduce the effects
of premature airway closure seen during forced spiro-
metry manoeuvres. Interference from upper airways arte-
facts such as tongue movement or swallowing can make
assessment difficult. Patients undergoing IOS do need
some coaching for accurate measures to be made.
Inert gas washout
Gas washout techniques were introduced in the 1950s as a
way of measuring the efficiency of gas mixing within the
lungs. This is dependent on the structure of both the large
and small airways and hence information regarding these
can be inferred from the tests. The most commonly
employed technique is the single breath nitrogen washout
(SBNW) and more recently the multiple breath nitrogen
washout (MBNW). Other gases may be used including
helium and sulphur hexafluoride (SF6) whose physical
properties determine gas flow within the lung.
Single breath nitrogen washout
The SBNW is performed by inhaling 100% oxygen from
RV to TLC followed by a SVC exhalation. The exhaled
volume and nitrogen concentration is measured and the
resulting trace can be broken down into four distinct
phases.
In phase I, the nitrogen concentration is close to 0% as
this represents anatomical dead space where there is no
gas mixing. During phase II, there is a sharp rise in the
expired nitrogen concentration as dead space gas mixes
with resident alveolar gas. Phase III represents alveolar
gas and the expired nitrogen concentration begins to
plateau, although there is a slight rise from the start
to finish of this phase due to ventilation heterogeneity.
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This occurs whenever two lung units are ventilated to a
different degree and the best ventilated unit will empty
preferentially before a less well-ventilated lung unit. In
health, this occurs to a degree because of asymmetry in
lung structure and due to the effects of gravity on the
base of the lung resulting in longer time constants for
emptying. Finally, in phase IV, there is a steep rise in
expired N2 concentration as the most poorly ventilated
areas (with little O2 mixing) empty. This is also the point
at which the small airways start to close as a result of
gravity-dependent collapse and is known as the closing
volume (CV). The CV and RV together are known as the
closing capacity (CC). Normally, small airways closure
occurs close to RV. However, small airways disease may
cause premature airway collapse resulting in an increased
CV and gas trapping. CV may be expressed as a ratio of
VC and should not exceed 25% (74). The CC may be
expressed as a ratio of TLC and is useful in obstructive
lung diseases.
Analysis of the slope of phase III (SIII) provides infor-
mation on the ventilation heterogeneity in the lung.
Airways diseases do not affect the lung uniformly and
this results in disparities in the ventilation of individual
subunits. This may occur in the conducting airways where
gas flows by convection (convection-dependent ventila-
tion inhomogeneity, CDI) and results from narrowing of
airways or increased stiffness in the subtended lung units.
It may also occur in the very distal acinar airways where
the diffusionconvection front arises (diffusionconvec-
tion-dependent inhomogeneity, DCDI). Here, it occurs as
a result of structural asymmetry between lung units (75).
Thus, where airways disease occurs, those affected lung
units mix less well with the inspired oxygen (and thus have
a higher nitrogen concentration) and empty more slowly.
This causes an increase in SIII.
SBNW indices have been used in the assessment and
response to treatment in both asthma and COPD.
Asthmatic patients with a normal FEV1 have increased
CV and phase III slope compared to healthy controls. In
addition, the frequency of exacerbations correlates with
SIII suggesting it may be a sensitive measure of patients
with poor control (76). Indeed, increased CV in patients
with severe asthma has been shown to be a risk factor for
predicting an exacerbation (77). Levels of exhaled mar-
kers of airway inflammation including nitric oxide
correlate with SIII and CC/TLC ratio in asthma (78, 79).
Furthermore, severe, steroid-dependent asthmatic pa-
tients have more marked changes in SBNW indices than
patients with mild to moderate asthma (79). These
markers have also been used to assess changes following
both inhaled and oral therapies for asthma (8083).
Over 35 years ago, the SIII of the SBNW was recognised
as being more closely related to histological small airways
inflammation in COPD than FEF2575 (29). Further
evidence of its association with small airways inflamma-
tion in COPD came from the examination of bronchial
biopsies and bronchoalveolar lavage (BAL) specimens
(84). COPD severity may also be predicted by changes in
SBNW indices as the SIII correlates with FEV1 (85) and
TLCO in alpha-1 antitrypsin deficiency (86).
SBNW is sensitive to early changes in airways in
smokers with an increase in CV (87), but its use is
controversial in COPD. Buist et al. demonstrated that
many smokers with normal spirometry, but abnormal
small airway indices, did not go on to develop obstructive
spirometry over a 911 year follow-up. However, of those
that did, the CC/TLC ratio predicted the rate of decline
in FEV1 suggesting it may be useful in identifying at risk
smokers (88). Sta˘nescu et al. similarly found that in a
group of smokers and ex-smokers with normal spirome-
try, over half had abnormal small airway indices, yet most
still had normal spirometry 13 years later. In their cohort,
a high SIII predicted accelerated decline in FEV1 (89).
Despite its sensitivity, the SBNW is not specific to
small airways pathology. Changes in any of the genera-
tions of the conducting airways will also affect the
slope of phase III. Thus, whilst it is possible to infer
that a normal SIII indicates no small airways disease, the
test is unable to locate the anatomical site of the
pathology (34).
Multiple breath nitrogen washout
The MBNW is a modification of the single breath
technique. The patient inhales 100% O2 from FRC with a
fixed tidal volume and respiratory rate to wash out the
resident nitrogen from the lungs. The test continues until
the exhaled nitrogen is less than 1/40th of the original
concentration (approximately 2%) for three successive
breaths. The speed and efficiency of gas mixing is deter-
mined by tidal volume, breath frequency, and ventilation
heterogeneity. Thus, by keeping breath frequency and tidal
volume relatively constant, inferences about ventilation
heterogeneity can be made (90). Figure 2 demonstrates the
nitrogen washout curves from a MBNW test.
This technique allows for measurement of the effi-
ciency of gas mixing in the whole lung through the lung
clearance index (LCI). It is defined as the number of lung
turnovers (FRC equivalents) required to wash out the
tracer gas to 1/40th of the original concentration. This is
calculated by measuring the cumulative expired volume
(CEV) required to washout the resident nitrogen and
dividing it by FRC:
LCI ¼ CEV
FRC
FRC may be calculated during the MBNW from the
following formula, whereby the volume of tracer gas (i.e.
N2) is divided by the end-tidal concentration of the tracer
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Fig. 2. (a) Multiple breath nitrogen washout curve with individual breaths demonstrating Phase III slope (SnIII) from 1st (b)
and 10th (c) breaths.
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gas in the first breath minus the end-tidal concentration
of the tracer gas in the last breath:
FRC ¼ V½tracer
Cint  Cend
The LCI has been used extensively as a measure of
airways function in cystic fibrosis and asthma, particu-
larly in the paediatric population (91).
As a MBNW progresses, the SIII of each breath changes
throughout the test, becoming steeper with successive
breaths. In order to compare breaths within a test, the
slopes must be normalised for the mean expired nitrogen
concentration for each breath (SnIII). In normal lungs, the
DCDI is the major determinant of the SnIII and reaches its
maximum at approximately 1.5 lung turnovers. After this,
the increase in SnIII is diffusion independent and hence
reflects CDI (92). This allows for the quantification of
the contribution of the CDI component, referred to as
Scond, and the DCDI component, referred to as Sacin (75).
Thus, these indices have the ability to anatomically locate
the site of the airway pathology that result in ventilation
inhomogeneity.
These indices have proven very sensitive, becoming
abnormal in smokers with more than a 10-year pack
history. In contrast, spirometric abnormalities only be-
come abnormal after a 20 pack-year history of smoking.
For smokers with a30 pack-year history and TLCOB
60% predicted, there were proportionately larger changes
in Sacin than Scond, reflecting parenchymal destruction
(93). Smokers without COPD who were able to stop
smoking showed sustained reversibility in Scond (94).
This supports the hypothesis that the major site of
pathology in smoking-related lung disease starts in the
peripheral airways.
These abnormalities have been further described in
both asthma and COPD. Verbanck et al. demonstrated in
COPD patients that both Scond and Sacin are raised yet
reflect different pathologies. Scond correlated with airways
measures such as FEV1 and specific airways resistance
whilst Sacin was more closely associated with diffusing
capacity (95). Asthmatic patients also have raised Scond
and Sacin, although acinar ventilation heterogeneity is less
pronounced than in COPD, presumably reflecting the
degree of parenchymal destruction in COPD. In addition,
asthmatic patients demonstrated bronchodilator reversi-
bility in both Sacin and Scond, whilst COPD patients did
not (96). In asthma, Sacin is more closely associated with
airway inflammation (97) and severity in unstable
patients (98). It has recently been shown that measures
of ventilation heterogeneity are associated with levels of
asthma control and may also predict the response to
inhaled therapy (99, 100). With their sensitivity to small
airways disease, they have been used in a variety of
research settings. These include the assessment of inhaled
treatments in both asthma (101, 102) and COPD (103),
assessment of airway hyper-responsiveness (104, 105),
and monitoring of lung transplant recipients (106).
However, they are not yet used in routine clinical practice
as there are few commercially available machines, and
interpretation of results can be difficult. Theoretically,
abnormalities in any of the conducting airways from the
first generation can cause abnormalities in Scond and
therefore it is not specific to small airways. Interpreting
the results with information from spirometry will help
clarify this. In addition, theoretical modelling for locali-
sation of airways disease was performed in normal
subjects. It is possible that the convectiondiffusion front
is different in disease states and hence anatomical
localisations may not be precise.
Helium and Sulphur hexafluoride washout tests
Other inert gasses including helium and SF6 may be used in
small concentrations as tracer gasses. These require a
wash-in period and specialised analytical equipment.
However, they have the added benefit that the physio-
chemical properties can be exploited to gain further
information from the SIII. The diffusion front of helium
lies more proximally than SF6 and therefore changes in the
helium SIII compared to SF6 SIII suggest more proximal
acinar changes. Where both SIII change so that the
difference between them is still the same, the possibilities
are either a change in the conducting airways or con-
comitant effects in the proximal and distal parts of the
acinus (34). There are fewer clinical studies reporting SF6
as a tracer gas and these have largely been performed in
children with cystic fibrosis (107109).
Exhaled nitric oxide
Nitric oxide is produced in both the resident airway
cells and the inflammatory cells in the lung and has a
role in the regulation of airway function. Fractional
exhaled nitric oxide (FENO) may be measured in a single
exhalation during tidal breathing. It reflects levels of
inflammation, particularly eosinophillic inflammation,
within the lung (110). Exhaled nitric oxide (eNO) exhibits
flow rate dependency, with an inverse correlation between
flow rate and FENO (111). This reflects both the transit
time of exhaled gas and diffusion from the tissue as well
as the compartment of the lung from which the NO was
produced. Under low flow conditions, FENO largely
reflects central airways and at higher flows it represents
alveolar NO (112114). This may help to localise the site
of inflammation within the lung. Indeed, Lehtima¨ki et al.
demonstrated that patients with alveolitis had higher
levels of alveolar NO than asthmatic patients, who in
turn have higher bronchial NO. In patients with alveolitis,
alveolar NO correlated with transfer factor and alveolar
volume, whilst bronchial NO correlated with airways’
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hyper-responsiveness in asthmatic patients. Both groups
of patients showed an improvement in FENO with steroid
treatment, suggesting it is responsive to intervention
(115). However, back-diffusion of NO between the
alveolar and airway compartments complicates the inter-
pretation of results. It has been recognised that NO will
diffuse from the airways down a concentration gradient
into the alveoli, thus elevating alveolar NO and reducing
measured airway NO (116, 117). Models to correct this
have been developed, however, in disease states where
airways are narrowed or occluded; less NO can back-
diffuse, resulting in higher FENO and lower alveolar
concentrations (118). It should also be noted that current
smoking reduces FENO levels and thus the smoking
status of a patient needs to be taken into account when
interpreting results (110).
FENO has been used extensively in asthma clinical
research and practice. Central airways appear to be the
major sites of production of NO in asthma both in stable
populations and during exacerbations (119). Alveolar
NO concentrations are raised in severe asthmatics where
they correlate with alveolar eosinophillic inflammation
(120) and other measures of small airways dysfunction
(121). Recently, it has also been shown that alveolar NO
is also raised in patients with mild asthma (122). FENO is
improved by both oral (123, 124) and inhaled corticos-
teroids (ICS) (125) and a raised FENO level before ICS
treatment predicts an improvement in asthma control
(126). This has made FENO an attractive prospect for
adding to asthma treatment algorithms. However, the
results of studies assessing impact of measuring FENO
have been mixed. Meta-analyses suggest no overall benefit
to asthma control and quality of life, but there is a
reduction in ICS use in adults although an increase in
ICS use in children (127, 128).
The role of FENO in COPD is less clear. FENO may be
raised in COPD (129131), although it is lower compared
to asthmatic patients. An inverse correlation with FEV1,
transfer factor, and oxygen saturations has been reported
(129). Contrary to this, Gelb et al. found no difference in
baseline alveolar or airway NO levels between healthy
controls and aged-matched COPD patients. Despite this,
the addition of salmeterol 50 mcg/fluticasone 250 mcg
combination inhaler significantly reduced airway, but not
alveolar NO. There was no correlation between emphy-
sema score and exhaled NO parameters (119). Higher
FENO levels may help predict a clinical response to ICS
as assessed by FEV1 reversibility (132) and this is
associated with a higher sputum eosinophil count (133).
Imaging of the small airways
Imaging already plays an extensive role in the management
of airways disease and can be used as a non-invasive
measure of small airways function. Where global measures
of lung function such as spirometry may classify patients
of the same severity, imaging is useful in separating
different phenotypes and localising heterogeneity. How-
ever, direct measurement of small airways is difficult as
they are largely beyond the resolution of CT and MRI
scanners. Nevertheless, both large airways have been
assessed directly and the smaller airways by their impact
on gas trapping and ventilation distribution. This pro-
vides both anatomical and functional information to the
physician.
High resolution CT
The small airways are beyond the resolution of CT
scanners and difficult to assess directly (134). Airways
as small as 22.5 mm in diameter can be visualised.
McDonough et al. found fewer of these airways in
patients with COPD undergoing CT lung cancer screen-
ing. The reduction in airway number worsened as COPD
severity increased by stage, consistent with pathological
findings in lung specimens (135). However, the accuracy
of measurement of smaller airways may be problematic
due to measurement error and artefact from breathing or
cardiogenic oscillations. Nakano et al. demonstrated that
measurement of intermediate-sized airways could predict
the small airway dimensions measured by histology (136);
thus, assessment may still prove useful in estimating the
extent of small airways disease. Quantitative assessment
of more proximal airway luminal diameter and airway
wall thickening measured by CT correlate with lung func-
tion in COPD (137140), with the strength of correlation
increasing for more distal airways (139).
Small airways disease results in gas trapping and may
be seen as areas of low attenuation distal to the site of
obstruction. Mosaic attenuation reflects localised areas
of gas trapping and suggests heterogeneous distribution of
airways disease. It may be seen in both asthma (141) and
COPD (142). However, gas trapping is best assessed on
expiratory scans and may provide an indirect measure of
small airways function (143). Comparing the mean lung
density between expiratory and inspiratory CT provides a
quantitative measure called MLDE/I. In asthma, MLDE/I
correlates strongly with FEV1, FEV1/FVC ratio, FEF2575,
and RV/TLC, suggesting that it reflects small airways
disease (144). In children, gas trapping has been shown to
be associated with improvements in post-bronchodilator
R5 and X5 measured by IOS (145). Gas trapping is more
marked during acute exacerbations of asthma and shows
responsiveness to steroids (146). Asthmatic patients with
gas trapping are more likely to have had asthma-related
hospital admissions, intensive care treatment, high levels
of airway neutrophils, and more severe airflow obstruction
than those without (147). ICS have been shown to improve
gas trapping in asthma, although in these small studies no
significant benefit in lung function or spirometry was seen
(148, 149).
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The assessment of gas trapping in COPD is more
complicated as both small airways disease and emphyse-
ma give rise to low attenuation areas. Visual estimation of
emphysema provides better correlation with lung func-
tion measures such as TLCO, whereas MLDE/I correlates
well with lung function measures of gas trapping (150). In
a large cohort of patients in the COPDGene study,
expiratory scans with a threshold of 856 Hounsfield
units (HU) for assessment of gas trapping had a stronger
correlation with airflow obstruction than emphysema
scores measured by the area of lung with 950 HU on
inspiratory scans. The volume change between inspira-
tory and expiratory scans also reduced as COPD severity
increased, reflecting more severe airway obstruction and
gas trapping (151). Using MLDE/I scores to assess gas
trapping and the 15th percentile of lung density to assess
emphysema, Hartley et al. demonstrated that small air-
ways disease contributes more strongly than emphysema
to severity of COPD (152). MLDE/I also correlates with
inflammatory changes measured by sputum neutrophils,
adding further support to the inflammatory nature of
small airways disease in COPD. MLDE/I is sensitive to
early small airways changes and correlates with SIII in
SBNW in a group of asymptomatic, non-smokers (153).
However, MLDE/I can show considerable variation
between scans in individual patients and therefore may
be difficult to use as a marker of response to treatment.
Recently, in the research arena, static images obtained
with CT have been made more functional by means of
computational fluid dynamics (154) and biomarkers
based on CT imaging have been developed that allow
an assessment of functional small airways disease (155).
Whilst CT is a useful, non-invasive tool for indirectly
assessing small airways function, it has a number of
limitations. The exposure to radiation means that re-
peated assessment for monitoring is not feasible. There is
no standardised measure of gas trapping at present and
different authors have used different density thresholds
for assessing gas trapping, making comparison more
difficult. Gas trapping is not diagnostic for specific
airways diseases and patterns such as mosaic attenuation
are also seen in pulmonary vascular disease (156).
Hyperpolarised helium magnetic resonance
imaging
Hyperpolarised helium magnetic resonance imaging (3He
MRI) allows for the assessment of distribution of
ventilation and morphometry of the distal airways and
lung parenchyma without exposure to ionising radiation
(157). Diffusion imaging visualises the movement of 3He
in the peripheral airspaces, bound by alveolar and air-
ways walls. This is calculated as the apparent diffusion
co-efficient (ADC) and gives insight into the microstruc-
ture of the distal airspaces (158). ADC is increased in
healthy smokers with normal lung function and correlates
with smoking history (159, 160), suggesting it is a
sensitive marker of early damage. It is increased further
in COPD where it correlates with lung function (161) and
emphysematous destruction (162). Indeed, ADC corre-
lates well with CT-derived emphysema scores and more
strongly with TLCO than CT-derived emphysema scores
(163). In COPD patients observed over 26 months, ADC
and other parameters derived from 3He MRI have been
shown to decline whilst FEV1 remained stable, suggesting
it is also sensitive to change over time (164). Measuring
diffusion over longer periods allows the assessment of
collateral ventilation in emphysema (165, 166).
Quantification of regional ventilation can be achieved
by both static and dynamic assessment of 3He distribu-
tion within the lung. Ventilation defects are present in
asthma (167, 168) and COPD (169, 170), resulting from
airway narrowing or obstruction and uneven ventilation.
In a group of asthmatic patients, the areas of ventilation
defects were persistent or recurred in the same locations
over time (169). Inflammatory cells obtained at bronch-
oalveolar lavage were more numerous in lobes with higher
ventilation defects that those without, suggesting that the
defects are the result of inflammatory airway narrowing
(171). Dynamic ventilation is a more recent advance that
allows imaging and assessment of ventilation with a high
spatial and temporal resolution over the course of a
respiratory cycle (161, 172). In asthma, areas of differ-
ential gas clearance have been observed that corroborat
with evidence of airflow obstruction and gas trapping on
CT (173).
Hyperpolarised MRI has the ability to assess regional
lung function which makes it a useful tool in assessing
airways diseases which have a heterogeneous distribution.
However, the technique is still largely restricted to
research applications and its role in the clinical manage-
ment of airways disease is not yet clear.
Nuclear medicine techniques
Two-dimensional gamma scintigraphy
Two-dimensional (2-D) gamma scintigraphy has been in
use for several decades. Gamma-emitting radionucleides
deposited within the lung can be imaged as they decay. This
allows for an assessment of the overall lung deposition and
to some extent, regional differences in deposition. Incor-
porating radionucleide into drug compounds is challen-
ging and hence an isotope bound to the drug such as 99mTc
is more commonly used. These techniques must be
validated to ensure that the addition of a radiolabel does
not significantly change the behaviour of the drug (174).
2-D gamma scintigraphy has been used to assess the
effect of particle size on deposition within the lungs.
Usmani et al. studied three particle sizes of radiolabelled
salbutamol and found that whilst small particle (1.5
micron) salbutamol was associated with a higher total
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lung dose and more peripheral deposition, it was the
large particles (6 micron) deposited in the more proximal
airways that had the greatest effect on bronchodilation
(13). In addition, the effect of late inhalation of a dry
powder demonstrated that a higher proportion reaches
the periphery of the lung without a change in the total
lung dose (175).
Whilst scintigraphy does involve exposure to ionising
radiation, the dose is low and is estimated at 0.15 mSv per
study (176). However, 2-D imaging does not allow precise
localisation of drug deposition as both central and small
airways as well as alveolar distribution may contribute to
gamma counts for any given area. Whilst assessment of
deposition is a useful marker of drug distribution, it does
not itself provide an assessment of clinical or physiological
response. Hence, these studies must be assessed along with
clinical and physiological data in order to evaluate efficacy.
Single photon emission computed tomography
Single photon emission computed tomography (SPECT) is
a 3-D imaging modality using multiple gamma detectors
that rotate around a supine patient. Reconstruction of the
images can demonstrate the radionucleide distribution in
three dimensions, thereby offering superior assessment of
regional lung ventilation or particle distribution. SPECT
may be combined with X-ray CT to relate the radionuclide
distribution to anatomical information (177, 178). SPECT
can be used to image ventilation using either radiolabelled
gasses or ultrafine particles such as Technegas†. This is an
ultrafine carbon particle labelled with 99mTc that has been
shown to have a similar inhaled distribution in healthy
patients to gases (179). This allows measurement of the
extent of regional distribution of airflow. In healthy
patients, airway closure measured with SPECT correlates
with CC measured by SBNW. However, in asthmatic
patients this correlation is lost, possibly due to regional
heterogeneity in airway closure (180). Technegas SPECT
has also been shown to identify regional EFL in asthma
even when flow measurements or negative expiratory
pressure techniques are insensitive to it (181). In COPD,
Technegas SPECT can identify regional differences in
emphysema which correlates with lung function and
emphysema scores (182, 183). The technique can be
combined with perfusion imaging to assess ventilation
perfusion relationships in the lung (184).
SPECT has proven a useful tool in defining the
deposition of inhaled drugs and can allow for treatments
to be more specifically targeted to areas of the lung.
Ciclesonide has been shown to have good peripheral lung
deposition, with low oropharyngeal deposition in both
health (185) and asthma (186). Limitations of SPECT
scanning include higher radiation doses to patients and a
longer acquisition time. This limits the assessment of
deposition of molecules with a fast clearance. However,
fast SPECT protocols have been developed with image
acquisition times under 1 min. This allows for assessment
of both deposition and clearance of tracers (187).
Positron emission tomography
Positron emission tomography (PET) is an emerging
technique for assessment of airways disease. It can be
used to assess drug deposition (188), inflammation (189),
and ventilation perfusion relationships in the lung (190).
However, PET scanners and the facilities to produce
radioisotopes are expensive. The radioisotopes used often
have a short half-life and incorporating them into drugs
is a complex process. However, it has the ability to
produce higher resolution images than SPECT and allows
for targeting of radioisotopes to specific receptors and
targets within the lung. Therefore, it is likely to be an area
of exciting research in the assessment of small airways
disease and treatment (191).
Conclusions
An understanding of the role of small airways in COPD
and asthma is increasingly important as it becomes
necessary to distinguish individual phenotypes of the
diseases. This will lead to a more tailored approach to
assessment and treatment of patients with the aim of
improving symptoms and function (192). It may also
allow us to reduce unnecessary exposure to treatments
that carry significant side effects. Given the anatomical,
functional, and physiological information that can be
obtained from these different tests, it is likely that a
combination of investigations will be required to give the
clearest picture of an individual’s phenotype. At present,
however, many of these investigations remain in the realm
of the research laboratory and further work is required to
understand their significance and interpretation in the
management of these diseases.
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